Press releaseGlobe Newswire
Crescent Biopharma
CBIO · NASDAQ
$13.07+$0.71 (+5.74%)TodayMarket closed ·
Prev close $12.36
Latest news
- Press releaseGlobe Newswire
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
- Press releaseGlobe Newswire
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Press releaseGlobe Newswire
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
- NewsAvi Kapoor
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results
- NewsAvi Kapoor
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
- NewsAvi Kapoor
ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- NewsAvi Kapoor
ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
- News
Crescent Biopharma Announces Regulatory Clearances Of IND Applications For CR-001, PD-1 X VEGF Bispecific Antibody, And CR-003, ITGB6-Targeted ADC, For Treatment Of Advanced Solid Tumors
- Press releaseGlobe Newswire
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
- News
Market-Moving News for December 4th
- Press releaseGlobe Newswire
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
- Press releaseGlobe Newswire
Crescent Biopharma to Present at September Investor Conferences
- NewsAvi Kapoor
Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsRishabh Mishra
US Stocks Likely To Open Higher Despite Trump's 'Unconditional Surrender' Call: All Eyes On Powell As Experts Predict Inflation Will Limit Fed's Rate Cut Capacity
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.